Diligence memo · auto-generated · as of July 2, 2026
Tetrous, Inc.
Tetrous, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Tetrous, Inc. operates in Biotechnology, based in SHERMAN OAKS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Tetrous, Inc. has raised $445K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $445K on 2023-12-12.
Most recent recorded round closed around 2023-12-12.
Valuation (modeled)modeled
Provath models Tetrous, Inc. at approximately $2.9M (range $237K–$12M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.90× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era. Within the normal band (90% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.6 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 9% of Biotechnology peers (4293 compared).
Modeled value ranks above 7% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.